This paper overviews the nationwide cancer statistics including incidence, mortality, survival and prevalence, and their trends in Korea based on the year 2008 cancer incidence data.
across the country every year. From 1999, the KCCR expanded cancer registration to cover the whole population under the Population-Based Regional Cancer Registry (PB-RCR) program. Details of the history, objectives, and activities of the KCCR have been documented [4] . Incidence data from 1999 to 2008 were obtained from the Korea National Cancer Incidence Database (KNCI DB). Cancer cases were classified according to the International Classification of Diseases for Oncology 3rd edition [5] and converted according to the International Classification of Diseases 10th edition (ICD-10) [6] . The survival analysis used 1,623,046 cancer cases first diagnosed during 1993-2008 from the KNCI DB, and followed the vital status through 31 December 2009.
Mortality data from 1983 to 2008 were obtained from the Korea National Statistics Office (KNSO) [1] . Cause of death was coded and classified according to the ICD-10. The population data were also obtained from KNSO using the resident registration population on July 1st of specified years.
A n a l y s i s
Crude rates (CRs) and age-specific rates of cancer incidence and mortality were calculated. Age-standardized rates (ASRs) were determined using the World Health Organization (WHO) world standard population [7] . The cumulative risks of cancer incidence, which represent the probability of developing cancer to life expectancy, were also calculated. Changes in the annual age-standardized cancer incidence rates were examined by calculating the annual percentage change over a time period as (exp(b)-1)x100, where b is the slope of the regression of log ASR on a calendar year [8] .
In order to assess the level of cancer burden, prevalence was also estimated which represents new and pre-existing cancer cases diagnosed during a given period of time and still alive on an index date. Using the cancer incidence database from 1999 to 2008, we calculated the limited-duration prevalence, such as 1, 5, and 10-year prevalence. In this study, for example, 10-year prevalence was calculated from the number of people alive on January 1, 2009 who were diagnosed with cancer within the previous 10 years. We applied the counting method Male  Female  Both sexes  Male  Female  Both sexes  Male  Female   All sites  178,816  93,017  85,799  68,912  43,785  25,127  724,663  334,329  390,334  Lip, oral cavity,  2,557  1,899  658  969  761  208  11,304  7,728  3,576  and pharynx  Esophagus  2,181  1,986  195  1,385  1,244  141  5,216  4,717  499  Stomach  28,078  18,898  9,180  10,312  6,712  3,600  134,722  89,616  45,106  Colon and rectum  22,623  13,536  9,087  6,802  3,809  2,993  103,033  60,448  42,585  Liver  15,663  11,776  3,887  11,292  8,512  2,780  36,036  27,085  8,951  Gallbladder   b)   4,378  2,149  2,229  3,459  1,698  1,761  9,935  5,076  4,859  Pancreas  4,320  2,404  1,916  3,767  2,135  1,632  4,780  2,663  2,117  Larynx  1,073  998  75  409  364  45  6,385  5,977  408  Lung  18,774  13,384  5,390  14,791  10,899  3,892  34,926  23,465  11,461  Breast  12,659  75  12,584  1,731  13  1,718  79,468  381  79,087  Cervix uteri  3,888  -3,888  954  -954  33,102  -33,102  Corpus uteri  1,562  -1,562  210  -210  9,084  -9,084  Ovary  1,816  -1,816  834  -834  9,732  -9,732  Prostate  6,471  6,471  -1,168  1,168  -23,940  23,940  -Testis  176  176  -14  14  -1,408  1,408  -Kidney  3,228  2,220  1,008  655  461  194  15,243  10,265  4,978  Bladde  3,230  2,582  648  1,007  752  255  18,260  14,845  3,415  Brain and CNS  1,620  876  744  1,040  568  472  6,273  3,289  2,984  Thyroid  26,923  4,275  22,648  347  108  239  107,693  15,252  92,441  Hodgkin lymphoma  210  127  83  46  31  15  1,253  796  457  Non-Hodgkin lymphoma  3,475  1,936  1,539  1,343  814  529  16,142  8,873  7,269  Multiple myeloma  893  480  413  615  316  299  2,464  1,295  1,169  Leukemia  2,561  1,432  1,129  1,507  867  640  9,936  5,442  4,494  Other and ill-defined  10,457  5,337  5,120  4,255  2,539  1,716  44,328  21,768 22,560 Includes gallbladder and other/unspecified parts of biliary tract.
using SEER*Stat software [9] to calculate the number of prevalent cases while adjusting for the patients lost in follow-up [8] .
The survival duration of each case was determined as the time difference between the date of initial diagnosis and the date of death, date of loss to follow-up, or closing date for follow-up. Observed survival rates were calculated using a life table method and relative survival rates were examined with the Ederer II method [10] using an algorithm written in SAS by Dickman [11] , with some minor modifications. sites combined were 176.9 and 101.9 per 100,000 for men and women, respectively. The ASRs of all sites combined were 154.1 and 63.5 per 100,000 for men and women, respectively. Cancers of the lung, liver, stomach and colon and rectum were the most common fatal cancers, which accounted for about 62.7% of all cancer deaths in 2008 (Table 4) . In men, the five leading primary cancer sites for mortality in 2008 were the lung (CR, 44.0; ASR, 38.7), liver (CR, 34.4; ASR, 28.5), stomach (CR, 27.1; ASR, 23.5), colon and rectum (CR, 15.4; ASR, 13.5), and pancreas (CR, 8.6; ASR, 7.5). In women, lung cancer mortality (CR, 15.8; ASR, 9.4) increased gradually being the first cancer site for mortality in 2008, followed by stomach (CR, 14.6; ASR, 8.7), colon and rectum (CR, 12.1; ASR, 7.3), liver (CR, 11.3; ASR, 7.2), and gallbladder (CR, 7.1; ASR, 4.1).
S e l e c t e d F i n d i n g s 1 Incidence

Trends in cancer incidence
Tables 5-7 present the cancer incidence rates during 1999-2008 in Korea for all sites combined and for selected cancer sites. The incidence rate for all sites combined increased by 3.1% annually from 1999 to 2008. The incidence rate for all sites combined increased by Cancer Res Treat. 2011;43(1):1-11
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Sites
Crude mortality rates/100,000 Age-standardized mortality rates/100,000 Includes gallbladder and other/unspecified parts of biliary tract. Includes gallbladder and other/unspecified parts of biliary tract.
1.5% annually in men and by 5.1% in women from 1999 to 2008. The rapid increase in cancer incidence is also illustrated in Fig. 1 .
As shown in Fig. 2 , the incidence rates have continued to increase for colon and rectum and thyroid cancer in both sexes, along with breast cancer in females and prostate cancer in males. On the contrary, the incidences of liver cancer in both sexes and cervix cancer in women have decreased. Stomach cancer incidence rates remained the same in men and women. One notable aspect was the sharp increase (25.4% annually) in the incidence of female thyroid cancer. As diagnostic techniques for thyroid cancer have become more sensitive, such as with the advent of ultrasound and fine-needle aspiration, the detection of subclinical disease has become possible. Therefore, the increased incidence of thyroid cancer may reflect improved diagnostic techniques for previously undetected disease, rather than a true increase in the occurrence of thyroid cancer [12, 13] . Furthermore, from the construction of a KNCI DB for 1999 onward to 2008, the completeness of the Korea cancer registry data has improved gradually. This might have contributed in part to the gradual overall increase in cancer incidence, especially among the elderly. Includes gallbladder and other/unspecified parts of biliary tract. stomach cancer was the most common in 35-64-year-olds, while lung cancer was more frequent for patients aged 65 and over. Thyroid cancer was the most common site for mid-aged Korean women (35-64-year-olds), and colorectal cancer was the most common among old aged women (≥65 year-olds). Fig. 3 shows the age-specific incidence rates of the selected cancers for men and women in 2008. The data show that the incidence of stomach, lung, liver and colorectal cancers increased gradually with age. Female breast and thyroid cancers showed highest incidence rates for women in their late forties and early fifties, respectively, and then leveled off. This pattern is very different from the rates observed in Western countries [14] .
Age-specific incidence rates for selected cancer sites
Trends in cancer mortality
Figs. 1 and 4 show the trends in cancer deaths for all sites combined and for selected cancer sites. Age-standardized mortality rates have decreased for all sites combined in both sexes since 2002. Lung cancer surpassed stomach cancer as the leading cause of cancer death in 1999, and is expected to account for 21.5% of all cancer deaths in 2008. The age-standardized mortality rates of lung have decreased slightly for men since 2001, but increased in women. The age-standardized mortality rates of stomach and cervix uteri cancer have decreased continuously. Along with the significant increases in colorectal, prostate and female breast cancer incidence, the mortality rates of these cancers have also continued to increase. had 5-year relative survival rates of 59.5% for all sites combined in both sexes, 50.8% in males and 69.2% in females. When compared with earlier periods, notable improvements have been observed in the 5-year relative survival rates for all sites combined. Observation of higher female cancer survival rates than male cancer survival rates may be partly explained by common female cancers (e.g., thyroid, breast, and uterine cervix) that are known to have relatively good prognoses.
Survival rates
When examined by the year of diagnosis and cancer site, the 5-year relative survival rates appeared to be higher for most major cancer sites in patients diagnosed during 2004-2008 compared to 1993-1995, except for pancreatic cancer. The greatest improvements were seen in prostate, stomach, leukemia, and non-Hodgkin lymphoma. The improving survival rates could be attributable to early detection, as well as to improved treatments [15, 16] , but this needs to be evaluated further. Lack of progress in early detection and treatment could explain the observed absence of improvement in the survival rate of pancreatic cancer [17] . Other and ill-defined Includes gallbladder and other/unspecified parts of biliary tract. 5 shows the prevalence by time since diagnosis. For all cancers combined, the 1-to 2-year prevalence represented 37% of the total prevalent cases. The 1-to 2-year prevalence as a percentage of the total was highest for thyroid cancer (18%) following stomach (16%), and colorectal cancer (14%), which has high incidence rates and a good prognosis. For all cancers combined, the 2-to 5-year prevalence and the 5-to 10-year prevalence constituted 33% and 30% of the total prevalence in both sexes, respectively. The long-term prevalence of lung and liver cancer was relatively low due to lower rates of survival.
Prevalence rates
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